# Phase 02 completion and readiness

Date: 2026-10-14

## Status

| Layer | State |
| --- | --- |
| Engineering acceptance | P02-F01 through P02-F05 are ACCEPTED as engineering records |
| Governance acceptance | Not accepted. Reviews P02-R01 through P02-R06 are PENDING |
| Production clinical authorization | Not authorized. Production and staging emergency access stay disabled |
| Phase register | IN_PROGRESS |
| Formal exit criteria | Not met. Evidence exists and is linked. No reviewer has accepted it |

Approvals received: none in `docs/identity/PHASE_02_APPROVALS.json`.

The charter approval by Benjamin Tetteh Nartey on 2026-10-13 covers `charter-2026.10` only. It does not sign Phase 02. The product owner cannot replace the architecture, security, or clinical reviewer. The constitution does not authorize one person to sign more than one of those three roles. No review in this file has a decision.

## What engineering completed
Server-side tenancy, Dex authentication, application TOTP and passkeys, default-deny `authorize()`, workforce lifecycle, and a development-only emergency read of `syn_kojo_agyeman`. Organization administrators do not have `billing.read` or `security.audit.read`. Emergency access is a branch inside `authorize()` after hard denials. It is not a bypass.

## Closeout commands on 2026-10-14
`npm test --workspace @curasphere/domain` exit 0. 206 passed, 0 failed. This run includes the Phase 02 domain scenarios and the Dex tests.

`npm audit --workspace @curasphere/domain --omit=dev` exit 0, 0 vulnerabilities.

`npm audit --workspace @curasphere/web --omit=dev` exit 0, 0 vulnerabilities.

The gateway virtualenv reports FastAPI 0.115.6 and Starlette 0.41.3 on Python 3.13.1. Those versions are unchanged from the Phase 01 finding. No new Trivy image scan was run. `gh` is not on PATH in this shell, so no GitHub Actions run was listed.

Earlier the same day, domain and web typechecks exited 0 and `npm run build --workspace @curasphere/web` exited 0 with the emergency routes present. Those commands were not repeated in this closeout.

## Exit criteria
| Criterion | Engineering evidence | Register |
| --- | --- | --- |
| Cross-tenant access tests prove isolation | P02-S44 and P02-F01 evidence. This closeout suite passed | Still pending reviewer acceptance |
| Privilege escalation tests pass | P02-S45, P02-S46, P02-S50, P02-S96. This closeout suite passed | Still pending reviewer acceptance |
| All access decisions are auditable | Authorization, workforce, and emergency event rows. Phase 03 retention is not built | Still pending reviewer acceptance |

The phase specification also requires reviewer sign-off when needed, before the phase is ACCEPTED. A clinical reviewer may later record a deferral of production role and emergency policy. That deferral is not recorded. Until it is, the phase stays IN_PROGRESS. The acceptance criteria were not changed.

## Decisions required
1. P02-R01 architecture reviewer: ACCEPT, REQUEST CHANGES, or REJECT ADR-0061.
2. P02-R02 security reviewer: ACCEPT, REQUEST CHANGES, or REJECT, including SEC-01 through SEC-07.
3. P02-R03 clinical reviewer: ACCEPT the development-only safety boundary, REQUEST CHANGES, or REJECT.
4. P02-R04 clinical reviewer: approve the role matrix, defer it, request changes, or reject it.
5. P02-R05 clinical reviewer: approve production emergency values, defer them, request changes, or reject them. Five minutes and fifteen minutes are not approved.
6. P02-R06 product owner: accept the phase only after the reviews governance requires.

Instructions: `docs/identity/PHASE_02_REVIEWER_DECISIONS.md`.

## Restrictions
Production deployment stays refused. Production clinical break-glass stays disabled. Phase 03 is not started. No regulatory classification is claimed.

## Packets
`docs/identity/PHASE_02_TRACEABILITY.md`
`docs/identity/PHASE_02_ARCHITECTURE_REVIEW.md`
`docs/identity/PHASE_02_SECURITY_REVIEW.md`
`docs/identity/PHASE_02_CLINICAL_GOVERNANCE.md`
`docs/identity/PHASE_02_ROLE_MATRIX.md`
`docs/identity/PHASE_02_EMERGENCY_INTENDED_USE.md`
`docs/identity/PHASE_02_RESIDUAL_RISK.md`
`docs/identity/PHASE_02_APPROVALS.json`
